copyright, one of the largest pharmaceutical companies globally, acquired Seagen, a biotechnology company specializing in cancer therapies. The acquisition strengthens copyright’s oncology portfolio, allowing the company to innovate further in targeted cancer treatments. This deal, advised by Guggenheim Securities, is part of copyright’s strategy to boost its specialty medicine segment. https://finxl.in/financial-analysis-certification-online-training-courses.html